Owkin Announces Partnership with AstraZeneca to Develop an AI …
WEB1 day ago · PARIS, October 02, 2024--Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new ...
Media center - Owkin
WEBDiscover our latest news on drug discovery, diagnostics, techbio, and AI.
Owkin, AstraZeneca partner to develop an AI gBRCA prescreen …
WEB5 hours ago · AI biotech company Owkin announced a partnership with pharma giant AstraZeneca to develop an AI-powered tool designed to prescreen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.. According to Owkin, BRCA testing, which identifies mutations in the BRCA1 and BRCA2 genes, plays an important role in deciding a person's risk for developing certain cancers ...
Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In …
WEBMay 23, 2024 · Owkin unveiled its precision AI drug pipeline in oncology & immunology and in-licensed OKN4395, a highly selective and potent EP2/4 dual antagonist.
Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In …
WEBMay 23, 2024 · Today, Owkin has unveiled its precision AI drug pipeline in oncology & immunology. To accelerate time-to-patient impact, Owkin has in-licensed OKN4395, a highly selective and potent EP2/4 dual...
Owkin Announces Partnership with AstraZeneca to Develop an AI …
WEB17 hours ago · About Owkin. Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment. We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient …
Owkin becomes ‘unicorn’ with $180m investment from Sanofi
WEBNov 18, 2021 · Owkin and Sanofi are delighted to announce that Owkin is now a ‘unicorn’ – a startup valued at more than $1 billion – through a new $180 million investment from Sanofi. Alongside the investment, Owkin and Sanofi are also announcing a strategic multi-year collaboration to research new treatments for four cancers.
Owkin enters collaboration agreement with MSD to develop AI …
WEBDec 19, 2023 · Owkin, which currently has the only MSI digital pathology diagnostic CE-marked in colorectal cancer, will extend the development of its MSI-H AI diagnostics into four new cancer types, leveraging...
TechBio Unicorn Owkin Teams Up with AWS to Advance …
WEBFeb 8, 2024 · Owkin selects Amazon Web Services (AWS) as its primary cloud provider to develop generative AI applications and accelerate drug discovery and development.
Owkin bags $180m BMS alliance for cardiovascular clinical trials
WEB3 days ago · Owkin has enticed another big pharma partner with its artificial intelligence-powered clinical development platform, Bristol-Myers Squibb, which is paying $80 million upfront to tap into its...
- Some results have been removed